Literature DB >> 29058268

Early diagnosed cerebrotendinous xanthomatosis patients: clinical, neuroradiological characteristics and therapy results of a single center from Turkey.

Tanyel Zubarioglu1, Ertugrul Kiykim2, Gozde Yesil3, Duhan Demircioglu4, Mehmet Serif Cansever5, Cengiz Yalcinkaya6, Cigdem Aktuglu-Zeybek2.   

Abstract

Cerebrotendinous xanthomatosis (CTX) is a lipid storage disorder caused by defective sterol 27-hydroxylase activity. In spite of subtle clinical signs beginning from childhood, CTX is generally diagnosed lately. The aim of this study is to evaluate clinical, neuroradiological findings and therapy responses of pediatric CTX patients and raise awareness to early features of disease. Patients who were molecularly diagnosed as CTX before 18 years of age were included in study. Clinical, epidemiological, radiological and genotypic features of patients and chenodeoxycholic acid (CDCA) therapy responses were reviewed retrospectively. Six patients were enrolled in the study. The mean age of diagnosis was 11.1 ± 4.5 years. Apart from previous studies, predominance of cerebellar signs over pyramidal signs, peripheral neuropathy with demyelinating neuropathy in majority of patients and pathological brain imaging findings despite young ages of patients were observed. Intention tremor was the consisting finding of all patients. Optic disc drusen was initially reported in one patient. Skeletal system involvement as coarse extremities, deformities and early osteoporosis was recognized in four patients. CDCA therapy improved or at least stabilized neurological functions in all patients. This study is the first CTX series from Turkey and performed among only in early diagnosed patients with a therapy follow-up contrary to limited data in the literature. We suggest that, awareness of intention tremor and ataxic gait in addition to mental retardation, peripheral neuropathy and early osteoporosis can be suspicious for CTX and lead diagnosis. Early treatment can provide stability and may also ameliorate existing neurological findings.

Entities:  

Keywords:  Cerebrotendinous xanthomatosis; Chenodeoxycholic acid therapy; Childhood; Early diagnosis

Mesh:

Substances:

Year:  2017        PMID: 29058268     DOI: 10.1007/s13760-017-0851-2

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  6 in total

1.  Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment.

Authors:  Andrea E DeBarber; Limor Kalfon; Ayalla Fedida; Vered Fleisher Sheffer; Shani Ben Haroush; Natalia Chasnyk; Efrat Shuster Biton; Hanna Mandel; Krystal Jeffries; Eric S Shinwell; Tzipora C Falik-Zaccai
Journal:  J Lipid Res       Date:  2018-08-22       Impact factor: 5.922

2.  Patients with cerebrotendinous xanthomatosis diagnosed with diverse multisystem involvement.

Authors:  Pelin Teke Kısa; Gonca Kilic Yildirim; Burcu Ozturk Hismi; Sevil Dorum; Ozge Yilmaz Kusbeci; Ali Topak; Figen Baydan; Fatma Nazlı Durmaz Celik; Orhan Gorukmez; Zumrut Arslan Gulten; Arzu Ekici; Serhat Ozkan; Aylin Yaman; Nur Arslan
Journal:  Metab Brain Dis       Date:  2021-03-11       Impact factor: 3.584

3.  Cerebrotendinous xanthomatosis with peripheral neuropathy: a clinical and neurophysiological study in Chinese population.

Authors:  Shu Zhang; Wei Li; Rui Zheng; Bing Zhao; Yongqing Zhang; Dandan Zhao; Cuiping Zhao; Chuanzhu Yan; Yuying Zhao
Journal:  Ann Transl Med       Date:  2020-11

4.  Follow-up of 25 patients with treatable ataxia: A comprehensive case series study.

Authors:  Mahmoud Reza Ashrafi; Elham Pourbakhtyaran; Mohammad Rohani; Bita Shalbafan; Ali Reza Tavasoli; Sareh Hosseinpour; Maryam Rasulinezhad; Zahra Rezaei; Ali Zare Dehnavi; Seyyed Mohammad Mahdi Hosseiny; Roya Haghighi; Homa Ghabeli; Morteza Heidari
Journal:  Clin Case Rep       Date:  2022-04-20

5.  Evaluation of the effect of chenodeoxycholic acid treatment on skeletal system findings in patients with cerebrotendinous xanthomatosis.

Authors:  Tanyel Zübarioğlu; İnci Pınar Bilen; Ertugrul Kıykım; Beyza Belde Doğan; Ece Öge Enver; Mehmet Şerif Cansever; Ayşe Çiğdem Aktuğlu Zeybek
Journal:  Turk Pediatri Ars       Date:  2019-07-11

6.  Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

Authors:  Shingo Koyama; Yoshiki Sekijima; Masatsune Ogura; Mika Hori; Kota Matsuki; Takashi Miida; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-08       Impact factor: 4.928

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.